Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 3

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 3
---
 mailed to Telomir stockholders on or about , 2025.

<div align='center'>TELOMIR PHARMACUTICALS, INC.

100 SE 2nd Avenue, Suite 2000 #1009

Miami, Florida 33131 (786) 3962-6723

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 30, 2025

Dear Stockholder of Telomir Pharmaceuticals, Inc.:</div>

On behalf of the board of directors of Telomir Pharmaceuticals, Inc., a Florida corporation (“Telomir”), we are pleased to deliver this proxy statement for a virtual annual meeting of stockholders of Telomir (the “TELO virtual annual meeting”).

Notice is hereby given that the TELO virtual annual meeting will be held on December 30, 2025, at 10:00 A.M. Eastern Time. To facilitate stockholder participation in the TELO virtual annual meeting, we have determined that the TELO virtual annual meeting will be held in a virtual meeting format only, via the internet, with no physical in-person meeting. You will be able to attend and participate in the TELO virtual annual meeting online by visiting to register for the meeting, where you will be able to listen to the meeting live, submit questions, and vote. To participate, vote or submit questions during the TELO virtual annual meeting via live webcast, you must register in advance at voteproxy.com prior to the meeting. Please note that you will not be able to attend the TELO virtual annual meeting in person. TELO is holding the TELO virtual annual meeting to consider the following proposals:

| 1. 
 2. 
 3. 
 4. | approve                                                                                                                                  
 the issuance of shares of common stock of Telomir, no par value per share (“TELO Common Stock”), or other securities                     
 of TELO pursuant to the proposed merger between TELO and TELI Pharmaceuticals, Inc., a Delaware corporation (“TELI”),                    
 pursuant to which TELOPHARM Acquisition Inc., a Delaware corporation and wholly owned subsidiary of TELO, will merge with and into       
 TELI, with TELI surviving as a wholly owned subsidiary of TELO (the “Merger”), which will represent (or are convertible                  
 into) more than 20% of the shares of TELO Common Stock outstanding immediately prior to the Merger, pursuant to Nasdaq Listing Rule